A.A. (Annemiek) van der Eijk

Annemiek A. van der Eijk studied medicine at the Erasmus University in Rotterdam from 1994-2000.
She conducted research on the clinical implications of quantitative HBV DNA measurements. Since completing her doctoral research, she has worked in the Viroscience department of Erasmus MC Rotterdam. She specialized as a medical-microbiologist / virologist in the Erasmus MC and as from 1 January 2010 she is medical head of the unit Clinical Virology Erasmus MC Rotterdam.

As a medical microbiologist and clinical virologist she performs expert consultations for patients of the Erasmus MC and for other hospitals within and outside the Netherlands. Furthermore she contributes to various response teams organized by the LCI during viral outbreaks, she is a frequently asked invited speaker, including her appearances on (news)radio and television. Furthermore, she actively translates her knowledge and expertise into (national) guidelines.

Her clinical research has been published in leading journals including the New England Journal of Medicine, Nature Communications, and other top-tier publications in her field.
Dr. van der Eijk has authored the virology training plan as an educator in the medical microbiologist training program, and she supervises and evaluates medical residents in training. Within Erasmus MC, she is a well-recognized colleague who plays an active role in various working groups. She is a member of the management team of the Core Laboratory, serves on the executive board of Diagnostics 2030, is a HIGH Performance Partner for Team NL NOC*NSF and acts as an IFMS coach for the re-registration process of other medical specialists within Erasmus MC. She is a board member of RODIN. RODIN aims to deepen and broaden knowledge in the field of infectious diseases.

Viral hepatitis and viral infections in immunocompromised patients with special attention for transplant patients and research on knowledge gaps of emerging viral infections.

Annemiek A. van der Eijk studied medicine at the Erasmus University in Rotterdam from 1994-2000. After obtaining her medical exams, she worked as a medical researcher at the MDL department of Erasmus MC, where she was supervised by prof.dr. S.W. Schalm and dr. R.A. de Man and conducted research into the clinical implications of quantitative HBV DNA measurements.

Since completing this PhD research, she has been working at the Viroscience department at Erasmus MC Rotterdam. She specialized as a medical-microbiologist / virologist and as from 1 January 2010 she is medical head of the unit Clinical Virology Erasmus MC Rotterdam. Her (research) focus areas include viral hepatitis and viral infections in immunocompromised patients with special attention for transplant patients and research on knowledge gaps of emerging viral infections. Furthermore she is High Performance Partner of the NOC*NSF Team NL and a member of the Response Team COVID-19 of the National Institute for Public Health and the Environment.

The Department of Viroscience is a member of:

• WHO Collaborating Center for Arboviral and Zoonotic diseases preparedness research and reference
• WHO National Reference Laboratory Centre - Measles & Rubella (together with RIVM)
• EU Reference Laboratories for Public Health research in influenza and respiratory infections
• National Reference laboratory for respiratory viruses (together with RIVM)
• National Reference laboratory for Arboviruses (together with RIVM)
• National Reference laboratory for viral hemorragic fevers (together with RIVM)

van der Eijk A - Search Results - PubMed

• Virology Supervisor: responsible for the virology component of the medical microbiology program. Written the virology component of the program.
• Actively involved in structured education for medical students and residents in training to become medical specialists, as well as incidental education for various clinical specialties: Minor in HPB.
• Viral Infections for Nurses
• Summer Campus010 for secondary education is looking for inspiring "Rotterdam residents" (2020).
• Collaboration between GIDS and Querido Honours College (students who can handle an additional social and scientific challenge (Medical students in society)): setting up microbiology education for schools in disadvantaged neighborhoods. (Link)
• Supervision of medical students in the field of "Introduction to Professional Practice"
• Virus expert (supervising projects with high school students)
• Erasmus MC Arts 2030: supervise field exploration
• Masterclass infection diseases viral hepatitis

• NVH Viral Hepatitis Working Group: Meeting of the HBV guideline working group (from 2025)
• Co-author of the National HBV Protocol for Solid Organ Transplantation Guideline (2024)
• Co-author of the National HCV Protocol for Solid Organ Transplantation Guideline (2024)
• RODIN Board Member
• Member management Team Core Lab
• Daily board member Diagnostics 2030
• Member of the IP&AMR Healthcare Network ZWN Medical Microbiologist
• Member of Platform Preparation Class A diseases (LCI)(since 2017)
• High Performance Partner NOC*NSF (since 2016)
• Infection Committee Erasmus MC (since 2009)
• Working Group Leader GFO unit clinical Virology (since 2009)
• Monkeypox Response Team 2022
• Participation in the expertise input for the National Functionality of Infectious Disease Control: work package Diagnostics and (preventive) treatment (2022)
• Participation in the development of the National Functionality for Infectious Disease Control (LFI), Diagnostics Working Group (2022)
• LINC Working Group Front Office Erasmus MC
• Management Team EraCore (Erasmus MC)
• Protocols for Elite Sport in the Rotterdam Region
• Assessor of elite sport protocols: safe sports during the coronavirus pandemic. Dozens of protocols assessed. • Protocol Compliance Officer UEFA/Feyenoord (2020-2021)
• Response Team Lassa 2019-2020
• LINC POCT (Laboratories Integration and Concentration): pre-analysis and front office working group & POCT working group (2015-2020)
• Response Team 2020-2023 Sars-CoV-2
• Erasmus MC OMT 2020-2022 Sars-CoV
• Attendance at Erasmus MC livestreams on the Sars-CoV-2 pandemic to inform Erasmus MC staff.
• Zika Virus Response Team (2016) (Diagnostic algorithm for Zika virus and pregnancy | LCI guidelines)
• Invited speaker EMA (European Medicines Agency) (2015), co-author of a reflection paper (Viral safety of plasma-derived medicinal products with respect to hepatitis E virus - Scientific guideline)
• June 12, 2015: Expert meeting - zoonoses (DB-Z) hepatitis E virus: invited as a speaker and to provide expert input.
• 2014 Member of the MERS-CoV Outbreak Investigation Team of the Netherlands
• Co-author of several LCI guidelines.

Training/Networking Organization

• Board Member of RODIN (Rotterdam Infectious Diseases Network)

• Viral Hepatitis Masterclass 2024

• Co-director of the Course in Virology Program 2021

• Residency Coordinator Virology for Medical Microbiologists in Training (since 2009)

• Coordinator of Medical Interns (since 2009)

• Course in Virology Coordinator 2016

• General Training Cluster 2 Leadership Program Erasmus MC: ‘Leadership on Course’ 2016 (completed)

• General Training Cluster 2 Leadership Program Erasmus MC: ‘Leadership on Course’ 2015 (completed)

Other

• Editor for BMC Infectious Diseases (2013-2014)

• Collaboration on the 5th edition of the Textbook Microbiology and Infectious Diseases, Chapter 11: Liver Infections (2022, first author of the chapter "Liver Infections")

• Quality Affairs Unit, Clinical Virology and Core Laboratory

• Functional Manager, LabTrain

• LabTrain course for AIOS

• METC, principal investigator in the Feyenoord study (completed)

• Protocol Compliance Officer, UEFA/Feyenoord (completed)

• Point of contact for Feyenoord regarding virological diagnostics and consultation

• Eurovision Song Contest 2021: As expert consultant, assessed Virology location and local guidelines and protocols to prevent SARS-CoV-2 spread during the festival.

• Virgo consortium:

Coordinator of research model 8.3 the Virgo consortium, funded by the Dutch government (FES0908), by the Netherlands Genomics Initiative (NGI) [project number 050-060-452] and by the European Community Seventh Framework Program [FP7/2007-2013] under project EMPERIE [grant agreement no. 223498] End 2015.

-  VIAGORAS from June 1, 2015 – May 31, 2019
-  HBV markers from April 1, 2016 – April 1, 2019
-  Validation fusion assays from April 1, 2016 – July 8, 2018

• Fujirebio

Project leader: Serological markers to screen and monitor past and present HBV infection and HCC. Financial support was provided by Fujirebio Europe, Ghent, Belgium, and the Dutch government (Health Holland-TKI-LSH, [project number LSHM15032]).

• IDLE project:

2024 Project coordinator: Improving detection and linkage to care in hepatitis delta. Sponsor: Foundation for Liver and Gastrointestinal Research, Rotterdam, the Netherlands, and financially supported by Gilead Sciences (IN-NL-980-7034). Neither party had any influence on study design, data analysis, manuscript preparation, or the decision to publish.